CRBN and autosomal recessive non-syndromic intellectual disability: This study allows a new conceptual view of how CRBN controls memory and provides a potential therapeutic intervention (namely, the pharmacological antagonism of CB1R) for patients with CRBN deficiency-linked ARNSID.